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Abstract
Background: Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is
approved for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezo-
lizumab in a broader, pretreated population, including patients ineligible for the pivotal
IMvigor211 phase 3 trial of atezolizumab.
Objective: To determine the safety and efficacy of atezolizumab in an international real-
world setting.
Design, setting, and participants: Between November 2016 and March 2018 (median
follow-up 12.7 mo), 1004 patients with locally advanced or metastatic urothelial or
nonurothelial urinary tract carcinomawho experienced progression during or after one
to three prior therapies for inoperable, locally advanced, or metastatic disease were
enrolled. Patients with renal impairment, treated central nervous systemmetastases, or
stable controlled autoimmune disease were eligible; 10% had Eastern Cooperative
Oncology Group performance status (ECOG PS) 2 and 98% were platinum pretreated
(Clinicaltrials.gov: NCT02928406).
zumIntervention: Atezoliy Current address: Hospital Universitario Marques de Valdecilla, Santander, Spain.
* Corresponding author. Englander Institute [46_TD$DIFF]of Precision Medicine, Weill Cornell Medicine, Belfer
Research Building, 413 East 69th Street, New York, NY 10021, USA. Tel. +1 646 9622072;
Fax: +1 646 9621603.
6@med.cornell.edu (C.N. Sternberg).E-mail address: cns900https://doi.org/10.1016/j.eururo.2019.03.015
0302-2838/© 2019 The Author(s). Published by Elsevier B.V. on behalf of Eur
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncab1200mgevery3 wkuntilprogressionorunacceptable toxicity.opean Association of Urology. This is an open access article
-nd/4.0/).
Outcome measurements and statistical analysis: The primary endpoint was safety.
Secondary efficacy endpoints included overall survival (OS), progression-free surviv-
al (PFS), and [5_TD$DIFF] overall response rate (ORR).
Results and limitations: The median treatment duration was 2.8 mo (range 0–19);
22% remained on treatment and 8% discontinued because of toxicity. Grade 3
adverse events occurred in 45% of patients. The most common grade 3 treatment-
related adverse events were fatigue, asthenia, colitis, and hypertension (each in 1%).
Median OS was 8.7 mo (95% confidence interval [CI] 7.8–9.9). The 6-mo OS rate was
60% (95% CI 57–63%), median PFS was 2.2 mo (95% CI 2.1–2.4), and the ORR was 13%
(95% CI 11–16%; 3% complete responses). Among IMvigor211-like patients (excluding
ECOG PS 2 and other IMvigor211 exclusion criteria), median OS was 10.0 mo (95% CI
8.8–11.9) and 6-mo OS was 65% (95% CI 61–69%).
Conclusions: SAUL confirms the tolerability of atezolizumab in a real-world pre-
treated population with urinary tract carcinoma. Efficacy overall and in the IMvi-
gor211-like subgroup is consistent with previous pivotal anti-PD-L1/PD-1 urothelial
carcinoma trials. These results support the use of atezolizumab in urinary tract
carcinoma, including patients with limited treatment options.
Patient summary: In this international study we investigated the efficacy and safety
of atezolizumab treatment for advanced urinary tract cancer in a large population of
pretreated patients, including those who would not normally be candidates for
clinical trials. Patients tolerated the treatment well, even if they had autoimmune
disease, were being treated with corticosteroids, or had disease that had spread to
their brain. Life expectancy in this study for patients typical of everyday clinical
practice was similar to that seen in trials [6_TD$DIFF] that[47_TD$DIFF] enrolled only selected fitter patients.
© 2019 The Author(s). Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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For 30 yr, chemotherapy was the mainstay of treatment for
metastatic urothelial bladder cancer, with infrequent
durable benefit. More recently, cancer immunotherapy
has improved the treatment of urothelial carcinoma and
five immunotherapeutic agents are approved in this setting
[1,2]. Cancer immunotherapy simultaneously targets sever-
al steps in the cancer [48_TD$DIFF]immunity cycle [3]. The rationale for
evaluating checkpoint inhibitors in urothelial carcinoma
stemmed from the high unmet medical need, the immu-
notherapeutic effect of bacillus Calmette-Guérin in bladder
cancer [4], the high incidence of somatic mutations, and the
resulting increase in neoantigens [5–8].
Atezolizumab, a humanisedmonoclonal antibody, targets
PD-L1, inhibiting its interaction with PD-1 receptors.
Atezolizumab also blocks binding of PD-L1 to B7.1 (CD80),
an interaction reported to provide additional inhibitory
signals to T cells [9]. Atezolizumab demonstrated encourag-
ing response rates in a phase 1 study in urothelial carcinoma
[8]. Long-term follow-up showed that good tolerability was
maintained with a durable clinical benefit [10]. The subse-
quent single-arm two-cohort IMvigor210 study of atezoli-
zumab in advanced or metastatic urothelial carcinoma
demonstratedmedianoverall survival (OS)of15.9 moamong
119 patients with advanced disease who were treatment-
naïve but cisplatin-ineligible [11] and median OS of 7.9 mo
among 311 patients whose disease had progressed on prior
platinum-based chemotherapy [12].
In the subsequent IMvigor211 phase 3 trial, patients with
disease progression during or following at least one
platinum-containing regimen for metastatic urothelialcarcinoma were randomised to either single-agent atezo-
lizumab or investigator-selected chemotherapy (vinflunine
or a taxane). Atezolizumab demonstrated a 13% overall
response rate (ORR), median progression-free survival (PFS)
of 2.1 mo, and median OS of 8.7 mo [13]. According to the
hierarchical design, statistical significance was not met for
the primary endpoint of OS for patients with PD-L1-positive
tumours (5% PD-L1-expressing tumour-infiltrating im-
mune cells [ICs]), precluding further statistical analysis.
Together, the available clinical evidence suggests that the
risk-benefit profile for atezolizumab is acceptable [46_TD$DIFF]in
patients with platinum-pretreated advanced urothelial
carcinoma, and atezolizumab was approved for this
indication in the USA and Europe. More recently, approval
of atezolizumab (and pembrolizumab) in the first-line
setting was restricted to patients[49_TD$DIFF] considered cisplatin
ineligible and with PD-L1-positive tumours (defined for
atezolizumab as 5% PD-L1-stained ICs), although the US
label allows atezolizumab for platinum-ineligible patients
irrespective of PD-L1 expression.
Similar to many previous trials in metastatic urinary
tract carcinomas, IMvigor211 excluded patients with
Eastern Cooperative Oncology Group performance status
(ECOG PS) >1, autoimmune disease, symptomatic brain
metastasis, inadequate renal function, or nonurothelial
histology. Such patients frequently present in clinical
practice, yet clinical evidence in these difficult-to-treat
populations is lacking [14]. To explore outcomes in these
understudied but prevalent populations, we initiated the
SAUL study in a population similar to that in IMvigor211 but
allowing patients for whom atezolizumab is indicated but
had not been systematically evaluated.
Table 1 – Baseline characteristics (safety population, n = 997)
Characteristic Result
Median age, yr (interquartile range) 68 (60–74)
Male, n (%) 772 (77)
ECOG PS at screening, n (%)
0 427 (43)
1 469 (47)
2 101 (10)
PD-L1 expression score, n (%)a
IC0 243 (24)
IC1 421 (42)
IC2/3 264 (26)
Missing 69 (7)
Number of prior lines for metastatic disease, n (%)b
0 382 (38)
1 543 (54)
2 52 (5)
3 20 (2)
Smoking history, n (%)
Current 167 (17)
Former 503 (50)
Never 327 (33)
Histological type, n (%)
Urothelial 950 (95)
Nonurothelial/mixed
Squamous cell carcinoma 18 (2)
Glandular 8 (1)
Bellini collecting duct 8 (1)
Neuroendocrine 7 (1)
Missing 6 (1)
Histological grade at diagnosis, n (%)
1 54 (5)
2 116 (12)
3 780 (78)
Missing 47 (5)
Location, n (%)
Bladder 744 (75)
Renal pelvis 122 (12)
Ureter 97 (10)
Urethra 10 (1)
Other 24 (2)c
TNM stage at diagnosis, n (%)
0is 12 (1)
0a 28 (3)
I 123 (12)
II 187 (19)
III 147 (15)
IV 488 (49)
Missing 12 (1)
TNM stage IV at study entry, n (%) 997 (100)
Prior platinum regimens, n (%)d
Any 975 (98)
Gemcitabine + cisplatin 530 (53)
Gemcitabine + carboplatin 416 (42)
MVAC 35 (4)
ECOG PS = Eastern Cooperative Oncology Group performance status;
IC0 = expression on <1% of tumour-infiltrating immune cells;
IC1 = expression on 1% to <5% of tumour-infiltrating immune cells[7_TD$DIFF]; IC2/
3 = expression on 5% of tumour-infiltrating immune cells;
MVAC = methotrexate, vinblastine, doxorubicin, cisplatin.
a PD-L1 expression was tested using the Ventana SP142 PD-L1
immunohistochemistry assay (Ventana Medical Systems, Tucson, AZ, USA).
b Patients whose disease relapsed within 12 mo of (neo)adjuvant treatment
were counted (for the purposes of eligibility) as having received first-line
treatment for metastatic disease.
c Includes eight with Bellini collecting duct tumours, ten with combinations
of more than one location, one reported as urachus, one reported as
intraprostatic, and four with unknown primary location.
d More than one answer was possible; treatment in the 22 patients (2%)
with no prior platinum comprised single-agent gemcitabine (n = 18), single-
agent vinflunine (n = 1), and other (n = 5).
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SAUL (Clinicaltrials.gov NCT02928406) is a single-arm multicentre
international open-label phase 3B safety study of atezolizumab in
locally advanced (T4bNany or TanyN2–3) or metastatic (M1) measurable
and/or nonmeasurable urothelial or nonurothelial carcinoma of the
urinary tract (bladder, ureter, urethra, or renal pelvis). Nonurothelial
carcinoma included all subtypes listed in the World Health Organization
classification. Patients with Bellini collecting duct tumours were eligible
if independently reviewed by two expert pathologists from different
sites. All patients were required to have ECOG PS 2 and disease
progression during or following one (subsequently amended to up to
three) prior platinum- or nonplatinum-based treatments (or intolerance
if they had received 2 cycles) for inoperable[50_TD$DIFF], locally advanced [51_TD$DIFF], or
metastatic disease. Patients with relapse within 12 mo of (neo)adjuvant
treatment were also eligible. If available, submission of representative
formalin-fixed, paraffin-embedded tumour samples was mandatory.
Patients with treated asymptomatic central nervous system (CNS)
metastases, autoimmune disease, concomitant corticosteroids, or renal
impairment were eligible provided they met the criteria shown in
Supplementary Table 1. Patients with prior allogenic stem cell or solid
organ transplantation, a history of idiopathic pulmonary fibrosis, active
hepatitis B or C, active tuberculosis, administration of a live attenuated
vaccinewithin 4 wk before study treatment initiation, or prior treatment
with CD137 agonists or immune checkpoint blockade therapies were
ineligible.
Patients received atezolizumab 1200 mg intravenously every 3 wk
until loss of clinical benefit, unacceptable toxicity, the patient's or
investigator's decision to discontinue therapy, or death. Concomitant
chemotherapy, hormonal therapy, immunotherapy, radiotherapy, or
investigational agents were prohibited.
The primary objective was to evaluate the safety of atezolizumab, as
measured by the nature, severity, duration, frequency, and timing of
adverse events (AEs) as recorded by investigators and graded according
to National Cancer Institute Common Terminology Criteria for Adverse
Events version 4.0. Supplementary Table 2 details AEs of special interest
(AESIs). Secondary objectives included evaluation of efficacy, including
OS, investigator-assessed PFS (per Response Evaluation Criteria in Solid
Tumours [RECIST] version 1.1), ORR (defined as a best response of either
confirmed complete or partial response per RECIST version 1.1), disease
control rate (DCR; defined as the sum of complete or partial response, or
stable disease for 4 wk), and duration of response (DoR; defined as the
time from first documented response to disease progression or death
from any cause). PFS, ORR, DCR, and DoR were also assessed using
modified RECIST (Supplementary Table 3). Additional secondary
objectives included evaluation of patient-reported outcomes and the
EuroQoL 5-Dimensions 5-Levels-assessed utility, results of which will be
reported separately, as will the duration and timing of AEs.
The planned sample size was 1000 patients. There was no formal
statistical hypothesis and all analyses are descriptive using standard
summary statistics. All time-to-event data (OS, PFS, and DoR) are
summarised using Kaplan-Meier estimates; medians are reported with
corresponding 95% confidence intervals (CIs). Subgroup analyses of
safety and/or efficacy according to the following factors were pre-
specified: ECOG PS 2; presence of CNS metastases at baseline; renal
impairment at study entry; positive human immunodeficiency virus
(HIV) status; history of autoimmune disease; concomitant steroid
therapy at baseline; and history of nonurothelial urinary tract carcinoma.
Exploratory analyses were performed for all remaining patients,
representing an “IMvigor211-like” more positively selected population.
Analyses according to the number of prior treatment lines for metastatic
disease were also prespecified.
During study treatment, patients were followed for safety at every
cycle. Tumourswere assessed every 9 wk for the first year and then every
Table 2 – Most common adverse events (any grade in 5% of patients, grade 3 or TR grade 3 in 1%; n = 997)
Adverse event Patients, n (%)
All grades Grade 3 Grade 4 Grade 5 TR grade 3
Any 880 (88) 352 (35) 59 (6) 37 (4) 127 (13)
Asthenia 184 (18) 20 (2) 2 (0.2) 0 8 (0.8)
Fatigue 173 (17) 24 (2) 0 0 10 (1)
Decreased appetite 163 (16) 10 (1) 1 (0.1) 0 1 (0.1)
Urinary tract infection 156 (16) 48 (5) 1 (0.1) 1 (0.1) 1 (0.1)
Anaemia 156 (16) 37 (4) 0 0 4 (0.4)
Pyrexia 137 (14) 5 (0.5) 0 0 3 (0.3)
Diarrhoea 137 (14) 8 (0.8) 0 0 4 (0.4)
Constipation 118 (12) 2 (0.2) 0 0 0
Nausea 109 (11) 2 (0.2) 0 0 0
Back pain 92 (9) 12 (1) 0 0 1 (0.1)
Pruritus 91 (9) 3 (0.3) 0 0 3 (0.3)
Vomiting 87 (9) 6 (0.6) 0 0 1 (0.1)
Arthralgia 82 (8) 10 (1) 0 0 2 (0.2)
Haematuria 78 (8) 14 (1) 0 2 (0.2) 0
Cough 70 (7) 1 (0.1) 0 0 0
Blood creatinine increased 60 (6) 6 (0.6) 1 (0.1) 0 0
Hypothyroidism 60 (6) 1 (0.1) 0 0 1 (0.1)
Dyspnoea 58 (6) 6 (0.6) 2 (0.2) 2 (0.2) 2 (0.2)
Abdominal pain 56 (6) 12 (1) 0 0 2 (0.2)
Rash 55 (6) 5 (0.5) 0 0 5 (0.5)
Peripheral oedema 51 (5) 3 (0.3) 0 0 1 (0.1)
Pain 41 (4) 13 (1) 2 (0.2) 0 0
Hyponatraemia 37 (4) 20 (2) 2 (0.2) 0 4 (0.4)
Hypertension 34 (3) 14 (1) 0 0 8 (0.8)
Urosepsis 14 (1) 10 (1) 2 (0.2) 2 (0.2) 0
Sepsis 13 (1) 6 (0.6) 4 (0.4) 2 (0.2) 1 (0.1)
Acute kidney injury 18 (2) 10 (1) 1 (0.1) 0 0
Intestinal obstruction 11 (1) 6 (0.6) 1 (0.1) 3 (0.3) 1 (0.1)
TR = treatment[8_TD$DIFF]-related.
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tinuation, patientswere followed for safety for 30 d after the last dose (or
until initiation of another anticancer therapy if earlier). Thereafter,
patients were followed for disease progression, selected AEs, further
anticancer therapy, and OS for up to 4 yr after enrolment of the last
patient.Table 3 – Subgroup analyses of safety
AE[1_TD$DIFF], n (%) All
[2_TD$DIFF](n [9_TD$DIFF] =[10_TD$DIFF] 997)
ECOG
PS 2
(n [9_TD$DIFF] =[11_TD$DIFF] 101)
CNS [12_TD$DIFF]
metastases
(n [9_TD$DIFF] =[13_TD$DIFF] 14)
[14_TD$DIFF]Renal
impairment
(n [9_TD$DIFF] =[15_TD$DIFF] 46)
[16_TD$DIFF]Auto-imm
disease
(n [9_TD$DIFF] =[17_TD$DIFF] 35)
Any grade AE 880 (88) 77 (76) 12 (86) 37 (80) 32 (91)
Grade 3/4 431 (43) 50 (50) 7 (50) 20 (43) 17 (49)
Grade 5 37 (4) 7 (7) 0 4 (9) 3 (9)
Treatment-related
AE
530 (53) 35 (35) 6 (43) 18 (39) 24 (69)
Grade 3 127 (13) 13 (13) 2 (14) 3 (7) 9 (26)
Serious AE 327 (33) 40 (40) 5 (36) 17 (37) 11 (31)
AESI 305 (31) 20 (20) 5 (36) 7 (15) 16 (46)
Grade 3 67 (7) 5 (5) 0 1 (2) 5 (14)
AE leading to
[27_TD$DIFF]treatment
discontinuation
57 (6) 3 (3) 0 3 (7) 3 (9)
[28_TD$DIFF]Median treatment
duration, months
2.8 0.7 1.4 3.0 5.6
AE = adverse event; AESI = AE of special interest; AID = autoimmune disease; CN
ECOG PS = Eastern Cooperative Oncology Group performance status; MD =
TD = treatment discontinuation; TRAE = treatment-related AE.
a All patients except those in subgroups excluded from the IMvigor211 phase 3 t
b Patients whose disease relapsed within 12 mo of (neo)adjuvant treatment.An independent data monitoring committee reviewed cumulative
safety data at regular intervals to ensure patient safety. The protocol and
all study-related materials were reviewed and approved by the
institutional review board or ethics committee at each site before study
initiation. All patients provided written informed consent before
undertaking any study-specific procedures.une [18_TD$DIFF]Concomitant
steroid
use (n [9_TD$DIFF] =[19_TD$DIFF] 40)
[20_TD$DIFF]Non-urothelial/[21_TD$DIFF]
mixed
(n [9_TD$DIFF] =[22_TD$DIFF] 47)
IMvigor211-likea[7_TD$DIFF]
(n [9_TD$DIFF] =[23_TD$DIFF] 643)
0 prior lines
for [24_TD$DIFF]metastatic
disease
(n [9_TD$DIFF] =[25_TD$DIFF] 382)b
38 (95) 40 (85) 577 (90) 339 (89)
23 (58) 24 (51) 261 (41) 176 (46)
3 (8) 0 20 (3) 7 (2)
22 (55) 25 (53) 355 (55) 210 (55)
4 (10) 5 (11) 81 (13) 52 (14)
19 (48) 16 (34) 200 (31) 123 (32)
14 (35) 15 (32) 201 (31) 124 (32)
2 (5) 3 (6) 46 (7) 27 (7)
2 (5) 2 (4) 37 (6) 24 (6)
1.4 2.1 3.5 2.8
S mets = central nervous system metastases; CSU = concomitant steroid use;
metastatic disease; NU/M = nonurothelial/mixed; RI = renal impairment;
rial.
[(Fig._1)TD$FIG]
Fig. 1 – Efficacy in the intent-to-treat population: (A) overall survival
(OS), (B) progression-free survival (PFS), and (C) duration of response.
CI = confidence interval.
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3.1. Patient population
Between November 30, 2016 and March 16, 2018,
1004 patients were enrolled from sites in Europe, Asia,
South America, Australia, and Canada (Supplementary
Table 4). Of these, 997 received atezolizumab. The remain-
ing seven patients did not start treatment because of signs
of clinical progression or deterioration or death.
Table 1 summarises the baseline characteristics. Overall,
35% of patients fell into at least one of the categories
ineligible for IMvigor211, including 10% with ECOG PS
2. Only two patients with HIV-positive status were
included. Almost all[52_TD$DIFF] patients (98%) had received platinum
at some stage during their previous therapy.
Among the 35 patients with autoimmune disease, the
most common were psoriasis (n = [53_TD$DIFF]15), rheumatoid arthritis
(n = 4), and autoimmune-mediated hypothyroidism or
thyroiditis (n = 3). Two patients had ulcerative colitis and
two had two concomitant autoimmune diseases. Among
the 40 patients receiving corticosteroids at baseline, three
(8%) also had CNS metastases (compared with a 1% overall
incidence of CNS metastases). Eight (8%) of 101 patients
with ECOG PS 2 were receiving corticosteroids at baseline [3_TD$DIFF]
compared with 4% overall. The most frequently adminis-
tered corticosteroids were dexamethasone (n = 14) and
prednisone (n = 9).
3.2. Treatment exposure
The data cutoff for the primary analysis was September 16,
2018. At this date, patients had received a median of five
cycles (range 1–28), corresponding to a median duration of
2.8 mo (range 0–19). The mean dose intensity was 1154 mg
(standard deviation 95) every 3 wk. Overall, 263 patients
(26%) received12 cycles,131 (13%) received18 cycles, and
39 (4%) received 24 cycles. Of the 600 patients with
recordeddiseaseprogressionat thedata cutoff, 269(45%)had
received one or more [54_TD$DIFF]cycles of atezolizumab after disease
progression (5 cycles after progression in 105 patients).
The most common reason for treatment discontinuation
was disease progression (66% of patients). Treatment was
discontinued because of AEs in 8% and consent withdrawal
in 3%. Treatment discontinuation peaked at cycle 3,
corresponding to the first tumour assessment (Supplemen-
tary Fig. 1). Treatment was ongoing in 220 patients (22%) at
the date of data cutoff.
3.3. Safety
The median duration of follow-up at the data cutoff was
12.7 mo (95% CI 11.8–13.2; range 0–19.7). AEs (any grade)
occurred in 880 patients (88%), the most common being
asthenia, fatigue, decreased appetite, urinary tract infec-
tion, and anaemia (Table 2). In 53% of patients, AEs were
considered by the investigator to be treatment-related.
Grade 3 AEs occurred in 45% of patients and were
considered treatment-related in 13%. The most commongrade 3 treatment-related AEs were fatigue, asthenia,
colitis, and hypertension (each in 1%). There were 37 grade
5 events (4%), of which seven were considered treatment-
related (colitis, intestinal perforation, dyspnoea [n = 2],
respiratory failure, chronic kidney disease, and drug-
induced liver injury).
AESIs were observed in 305 patients (31%); however, the
majority were grade 1/2. Grade 3 AESIs occurred in 7% of
patients, most commonly grade 3 immune-related hepatitis
diagnosed as a laboratory abnormality (3%). Two-thirds of
the grade 3 laboratory abnormalities were resolving or
had resolved by the data cutoff date; one case of
hyperbilirubinaemia was fatal.
Table 3 shows safety in difficult-to-treat populations that
were excluded from IMvigor211. Although comparisons are
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there was a suggestion that treatment-related AEs and
AESIs were more frequent among patients with autoim-
mune disease than in the overall population, and grade 3
AEs were more common among patients receiving cortico-
steroids at baseline. Overall, however, incidences in most of
the subgroups were similar to those in the overall
population. There was no signal of greater toxicity in
patients with ECOG PS 2.
3.4. Efficacy
At the data cutoff, 555 patients had died. Median OS was
8.7 mo (95% CI 7.8–9.9), the 6-mo OS rate was 60% (95% CI
57–63%), and the 1-yr OS rate was 41% (95% CI 38–44%;
Fig. 1A). Median PFS based on 797 PFS events was 2.2 mo
(95% CI 2.1–2.4; Fig. 1B) and 2.8 mo (95% CI 2.4–3.4)
according to modified RECIST.
The RECIST ORR was 13% (95% CI 11–16%), including
complete responses in 3%. The modified RECIST ORR was
14% (95% CI 12–17%). The DCR was 40% (95% CI 37–43%).
Median DoR is not mature but the lower limit of the 95% CI
for the median is 13.2 mo (upper limit not evaluable;
Fig. 1C).
As shown in Table 4 and Fig. 2, efficacy in difficult-to-
treat populations was generally consistent with results in
the overall population treated in SAUL, except for shorter OS
among patients with CNS metastases and significantly
worse OS, PFS, ORR, and DCR among patients with ECOG PS
2. In the converse IMvigor211-like population, median OS
was 10.0 mo (95% CI 8.8–11.9), the 6-mo OS rate was 65%
(95% CI 61–69%), and the 1-yr OS rate was 46% (95% CI 41–
50%). The ORRwas 14% (95% CI 11–17%), including complete
responses in 4%. Among patientswith no prior treatment for
metastatic disease (recurrence within 12 mo of [neo]
adjuvant therapy), median OS was 9.9 mo (95% CI 7.8–12.4).
4. Discussion
SAUL is the first large prospective clinical trial designed to
explore the safety of immunotherapy in advanced urothelial
cancer, including patient populations that are rarely
included in clinical trials. The prevalence of PD-L1 IC2/3
expressionwas similar in SAUL (26%) and IMvigor211 (25%).
Atezolizumab was well tolerated and safety results in the
SAUL real-world setting are consistent with previous
atezolizumab experience, despite the less selected popula-
tion. Treatment-related grade 5 AEs were observed in 0.7%
of patients; immune-related AEs were relatively infrequent.
Efficacy in the real-world population enrolled in SAUL is
similar to that in previous phase 3 trials of cancer
immunotherapy [13,15]. Among the two-thirds of patients
corresponding to an IMvigor211-like population (excluding
difficult-to-treat subgroups ineligible for IMvigor211),
median OS was 10.0 mo. This is within the range observed
with pembrolizumab in KEYNOTE-045 [15] and atezolizu-
mab in IMvigor211 [13]. These results further support the
use of atezolizumab in IMvigor211-like patients. Notably,
efficacy in patients who had received no prior therapy for
[(Fig._2)TD$FIG]
Fig. 2 – Efficacy in the overall population and prespecified difficult-to-treat subgroups. CNS = central nervous system; ECOG PS = Eastern Cooperative
Oncology Group performance status; OS = overall survival.
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population.
Currently many of the understudied patient populations
deliberately included in SAUL do not receive chemotherapy
and are ineligible for trials [16]. Results from SAUL provide
information for clinicians and patients on the feasibility of
immunotherapy in these populations. A previous retro-
spective analysis of patients with rheumatic disease before
or during anti-PD-1 therapy suggested a high rate of
rheumatoid flares [17]. In our analysis of patients with any
autoimmune disease, AESIs appeared to be more common
than in the overall population but treatment discontinua-
tion was infrequent. Poor efficacy in patients with ECOG PS
2 is difficult to interpret. The literature includes minimal
information on outcomes with chemotherapy or cancer
immunotherapy in this setting, although Necchi et al. [18]
reported more than twofold worse OS for metastatic
urothelial carcinoma patients with ECOG PS 2 compared
with ECOG PS 0. Similarly, outcomes for pembrolizumab-
treated melanoma patients with ECOG PS 2 were
significantly worse than for those with ECOG PS 1
[19]. We also observed short OS for patients with CNS
metastases treated in SAUL. Such patients are usually
excluded from clinical trials; the limited reports in the
literature suggest poor outcomes in these populations
irrespective of treatment [20,21]. The 95% CIs for efficacy
parameters in the subgroup of patients receiving cortico-
steroids at baseline overlap with those for the overall
population, although the suggestion of worse efficacy is
consistent with a previous retrospective study describing
significantly worse PFS and OS among patients with non-
small-lung cell cancer treated with anti-PD-1/PD-L1 who
were receiving steroids at baseline [22].
Limitations of SAUL include the single-arm design and
the relatively small patient numbers in some of the
understudied subgroups. Nevertheless, data for some of
the difficult-to-treat populations provide information onthe use of atezolizumab in patients for whom there was
previously little or no information on treatment outcomes.
For example, tolerability in patients with ECOG PS 2 was
similar to that in the overall population.
5. Conclusions
Results from SAUL in a real-world population demonstrate
that atezolizumab is a tolerable and effective treatment
for urinary tract carcinoma, even in complex comorbid
populations such as patients with renal impairment or
autoimmune diseases. These results generated in an
international real-world population provide reassurance
that atezolizumab can be offered to a broader range of
patients presenting in routine clinical practice and meeting
the approved indication for atezolizumab. Notably, efficacy
in SAUL was similar to that reported for atezolizumab in the
IMvigor211 phase 3 trial and other clinical trials of PD-L1
and PD-1 inhibitors. Final results are expected in 2022, 4 yr
after enrolment of the last patient.
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